Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKinsey
Dow
McKesson
Mallinckrodt

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

CAVERJECT Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Caverject patents expire, and when can generic versions of Caverject launch?

Caverject is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in CAVERJECT is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Caverject

A generic version of CAVERJECT was approved as alprostadil by WEST-WARD PHARMS INT on January 20th, 1998.

  Free Forever Trial

US Patents and Regulatory Information for CAVERJECT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer CAVERJECT alprostadil INJECTABLE;INJECTION 020379-003 Jun 27, 1996 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer CAVERJECT alprostadil INJECTABLE;INJECTION 020379-004 May 19, 1997 AP RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer CAVERJECT alprostadil INJECTABLE;INJECTION 020755-002 Oct 1, 1997 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CAVERJECT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer CAVERJECT alprostadil INJECTABLE;INJECTION 020379-003 Jun 27, 1996 ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer CAVERJECT alprostadil INJECTABLE;INJECTION 020379-002 Jul 6, 1995 ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer CAVERJECT alprostadil INJECTABLE;INJECTION 020379-002 Jul 6, 1995 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Baxter
McKesson
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.